EP4121066A1 - Agents contenant de l'or pour le traitement d'infections pulmonaires - Google Patents
Agents contenant de l'or pour le traitement d'infections pulmonairesInfo
- Publication number
- EP4121066A1 EP4121066A1 EP21712492.4A EP21712492A EP4121066A1 EP 4121066 A1 EP4121066 A1 EP 4121066A1 EP 21712492 A EP21712492 A EP 21712492A EP 4121066 A1 EP4121066 A1 EP 4121066A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- medicament
- aurothioglucose
- gold
- acetylcysteine
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010931 gold Substances 0.000 title claims description 60
- 229910052737 gold Inorganic materials 0.000 title claims description 59
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims description 49
- 208000032376 Lung infection Diseases 0.000 title claims description 12
- 238000011282 treatment Methods 0.000 title description 24
- 239000003814 drug Substances 0.000 claims abstract description 132
- 229960001799 aurothioglucose Drugs 0.000 claims abstract description 78
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims abstract description 75
- 208000019693 Lung disease Diseases 0.000 claims abstract description 39
- 208000015181 infectious disease Diseases 0.000 claims abstract description 38
- 239000000843 powder Substances 0.000 claims abstract description 37
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 18
- 230000002458 infectious effect Effects 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 229960004308 acetylcysteine Drugs 0.000 claims description 50
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 46
- 229940079593 drug Drugs 0.000 claims description 33
- 239000004480 active ingredient Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 241001678559 COVID-19 virus Species 0.000 claims description 16
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 15
- 229950008454 favipiravir Drugs 0.000 claims description 15
- 208000025721 COVID-19 Diseases 0.000 claims description 13
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 13
- 241000711573 Coronaviridae Species 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 10
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 claims description 10
- 229940075124 molnupiravir Drugs 0.000 claims description 10
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 9
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 9
- 229960000329 ribavirin Drugs 0.000 claims description 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 229940071648 metered dose inhaler Drugs 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 6
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 241001493065 dsRNA viruses Species 0.000 claims description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 4
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 4
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 4
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 4
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 4
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960003677 chloroquine Drugs 0.000 claims description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 4
- 229960002418 ivermectin Drugs 0.000 claims description 4
- 229960004525 lopinavir Drugs 0.000 claims description 4
- 229960000884 nelfinavir Drugs 0.000 claims description 4
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 4
- 229960000311 ritonavir Drugs 0.000 claims description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 4
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004626 umifenovir Drugs 0.000 claims description 4
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 229940041290 mannose Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 27
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 24
- 229960005207 auranofin Drugs 0.000 description 23
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 23
- 229940009100 aurothiomalate Drugs 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 101800004803 Papain-like protease Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 16
- 239000007995 HEPES buffer Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 12
- -1 gold ions Chemical class 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 150000002344 gold compounds Chemical class 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 208000006673 asthma Diseases 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 201000009961 allergic asthma Diseases 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000003435 antirheumatic agent Substances 0.000 description 8
- KBWWFTIQBJUOQR-UHFFFAOYSA-L aurotioprol Chemical compound [Na+].[Au+].[S-]CC(O)CS([O-])(=O)=O KBWWFTIQBJUOQR-UHFFFAOYSA-L 0.000 description 8
- 229940072304 aurotioprol Drugs 0.000 description 8
- 108010079530 gold keratinate Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940096437 Protein S Drugs 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 101710198474 Spike protein Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000002924 anti-infective effect Effects 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 7
- UCGZDNYYMDPSRK-UHFFFAOYSA-L trisodium;gold;hydroxy-oxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Na+].[Na+].[Na+].[Au].OS([S-])(=O)=O.OS([S-])(=O)=O UCGZDNYYMDPSRK-UHFFFAOYSA-L 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 241000711443 Bovine coronavirus Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 239000012907 medicinal substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 4
- 108700038444 SARS-CoV-2 papain-like protease Proteins 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 4
- 108010058907 Tiopronin Proteins 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 230000003356 anti-rheumatic effect Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 4
- 229960004986 pyritinol Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 229960004402 tiopronin Drugs 0.000 description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 150000002343 gold Chemical class 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229960001639 penicillamine Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 229960002563 disulfiram Drugs 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940076085 gold Drugs 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 230000007466 Aβ secretion Effects 0.000 description 1
- 101150011571 BSL2 gene Proteins 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 108700010904 coronavirus proteins Proteins 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical class [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the field of the present invention are medicaments for the treatment of lung diseases, preferably infectious and mixed inflammatory-infectious lung diseases.
- Infectious lung diseases are widespread and represent a major social problem.
- seasonal infections such as flu
- they are among the most common diseases, on the other hand, they are very often the direct cause of death in the elderly.
- the therapeutic options for viral and / or bacterial infections of the respiratory tract have so far been inadequate.
- SARS severe Acute Respiratory Syndrome
- SARS-CoV-1 coronavirus 1
- SARS-CoV-2 coronavirus 2
- MERS Middle East respiratory syndrome
- MERS-CoV coronavirus
- the target of the spike protein is the membrane protein ACE2 (angiotensin-2 converting enzyme), which plays an important role in renin-angiotensin
- ACE2 angiotensin-2 converting enzyme
- the system plays by enzymatically splitting the angiotensin-2, which increases blood pressure, and thus becoming its direct opponent in the physiological process.
- ACE inhibitors and AT2 antagonists are particularly important in life Extending drug classes for treating high blood pressure and preventing strokes and heart attacks. They work in the same direction as the physiological ACE2. Thus, every infection with SARS-CoV-2 also means a disruption of the function of one of the most important physiological systems.
- nucleoside analogue remdesivir is sometimes used as an antiviral therapy for SARS-CoV-2.
- Other therapeutic approaches are aimed at the excessive reaction of the immune system, for example with the steroid dexamethasone.
- the present invention therefore provides medicaments for inhalation containing gold, preferably aurothioglucose, available.
- Medicinal substances containing gold are traditionally used in basic anti-rheumatic therapy.
- the use of the most frequently used drugs auranofin, aurothiomalate and aurothioglucose has been suppressed more and more in recent years despite their good efficacy due to the development of biologics and the frequent occurrence of undesirable side effects in long-term therapy.
- gold compounds have a strong anti-inflammatory effect, this being attributed to the inhibition of the nuclear factor NFkappa B. This factor also plays a central role in cystic fibrosis and interstitial pneumonia, which are feared as a consequence of viral lung infections, among other things.
- auranofin has a considerable antibacterial and antibiofilm effect (AbelKhaleka et al, 2019).
- Aurothioglucose also has antimicrobial activity (Elkashif and Seleem, 2020).
- An antiviral effect has been described for gold nanoparticles (Rodriguez-Isqierdo et al., 2020). The antibacterial effectiveness has not yet become the subject of approved drugs.
- WO 2017/093544 A1 describes alkynylphosphine-gold complexes for the treatment of bacterial infections.
- WO 2017/058012 A1 discloses gold (III) compounds for the treatment of COPD and asthma.
- WO 2012/142615 A2 describes Auranofin and Auranofin analogs for the treatment of proliferative diseases.
- WO 2021011466 A1 describes metal-nanoparticle compositions for the treatment of respiratory infections associated with cystic fibrosis.
- KR 2015/0144679 A discloses compositions for the prevention and treatment of immune diseases containing mesenchymal stem cells treated with a STAT3 inhibitor.
- WO 2016/201524 A1 discloses a method for producing metal ion complexes, in which the metal in particle form is brought into contact with a chelating agent and a metal complex is formed with the aid of an oxidizing agent.
- aurothioglucose has a high affinity for the spike protein of the SARS-CoV-2 virus. This also has a cysteine-rich domain to which the virus binds so strongly that ACE2, the virus’s natural point of attack, is efficiently displaced from the binding. Since the spike protein-ACE2 interaction is crucial for the virus to attack the body's cells, this finding shows that the antiviral effect of gold compounds is also based on a specific prevention of infection before the virus enters the body's cells. As a result, these compounds are also suitable for use in medicaments for the prevention of infection.
- the anti-infective property is added to the other antimicrobial and immunomodulatory properties and makes gold medication for inhalational use unique drugs for topical therapy of spike protein-associated infections, especially SARS-CoV-2 infections. Because of their special properties, the medicaments according to the invention are also particularly suitable for the prevention of viral infections.
- the present invention therefore relates to a medicament for inhalation which has a dual effect - at the same time anti-infective and anti-inflammatory-immunomodulatory - preferably a medicament which contains a medicinal substance containing gold, such as aurothioglucose, aurothiomalate, auranofin, aurothiosulfate, aurotioprol and aurothiopolypeptide , or contains the gold salt of a sulfur-containing drug, such as acetylcysteine, pyritinol, tiopronin and penicillamine.
- a medicament which contains a medicinal substance containing gold, such as aurothioglucose, aurothiomalate, auranofin, aurothiosulfate, aurotioprol and aurothiopolypeptide , or contains the gold salt of a sulfur-containing drug, such as acetylcysteine, pyritin
- the gold salt of N-acetylcysteine is a particularly preferred compound because N-acetylcysteine is already the drug acetylcysteine used for the treatment of lung diseases and a positive therapeutic additional effect can be expected.
- the counterion is also of great importance.
- the toxic phosphine part of Auranofin limits its possibilities for dosing considerably.
- the gold ion is also released from the connection the counterion co-determined to a large extent.
- the respective therapeutic relevance of the anti-infective or anti-inflammatory immunomodulatory effect is dependent on time. While the inhibition and spread of infection are of particular importance in the early phase of the disease, immune modulation is of particular importance in the later phases and especially in the case of severe courses.
- the binding of the gold ion to the spike protein can be significantly improved by a further compound that contains a mercapto group, which makes it possible to control the activity profile of the drug so that either the anti- Infective profile before resorption (when activated) or the anti-inflammatory-immunodulatory profile after resorption (without activation) is in the foreground.
- Another object of the invention is therefore a combination medicinal product in which the gold-containing compound is combined with a mercapto group-containing compound, preferably with N-acetylcysteine.
- the invention relates to a medicament for inhalation containing gold, preferably aurothioglucose, aurothiomalate, auranofin, aurothiosulfate, aurotioprol, aurothiopolypeptide, and / or the gold salt of a sulfur-containing medicinal substance (preferably N-acetylcysteine, pyritinol, tiopronin and / or penicillamine), especially aurothioglucose.
- gold preferably aurothioglucose, aurothiomalate, auranofin, aurothiosulfate, aurotioprol, aurothiopolypeptide, and / or the gold salt of a sulfur-containing medicinal substance (preferably N-acetylcysteine, pyritinol, tiopronin and / or penicillamine), especially aurothioglucose.
- the medicament also contains N-acetylcysteine.
- the medicament contains a further active ingredient, preferably wherein the further active ingredient has an antiviral and / or antibacterial effect.
- the drug contains a virostatic agent, preferably selected from the group consisting of remdesivir, molnupiravir, favipiravir, ribavirin, lopinavir, umifenovir, nelfinavir and / or ritonavir, preferably favipiravir, molnupiravir and / or ribavirin, especially favipiravir.
- the combination of aurothioglucose and aurothiomalate with one of the preferred antivirals has proven to be particularly advantageous.
- the medicament containing the antiviral additionally contains N-acetylcysteine (for example as a triple combination containing gold, in particular aurothioglucose, N-acetylcysteine and a virostatic, in particular the combination aurothioglucose + N-acetylcysteine + favipiravir or the combination aurothioglucose + N-acetylcysteine + Molnupi ravir).
- N-acetylcysteine for example as a triple combination containing gold, in particular aurothioglucose, N-acetylcysteine and a virostatic, in particular the combination aurothioglucose + N-acetylcysteine + favipiravir or the combination aurothioglucose + N-acetylcysteine + Molnupi ravir).
- the drug contains an active ingredient selected from hydroxychloroquine, chloroquine and / or ivermectin.
- the medicament preferably also contains N-acetylcysteine (e.g. as a triple combination containing gold, in particular aurothioglucose, N-acetylcysteine and an active ingredient selected from hydroxychloroquine, chloroquine and / or ivermectin).
- the medicament (with or without N-acetylcysteine) additionally contains a virostat as described herein.
- the invention provides an inhaler, preferably a powder inhaler, metered dose inhaler or nebuliser, containing a medicament according to the invention.
- the invention provides the medicaments according to the invention for use in prevention or therapy of lung diseases, preferably in the prevention or therapy of inflammatory, infectious and mixed inflammatory-infectious lung diseases, in particular SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), or Covid-19.
- lung diseases preferably in the prevention or therapy of inflammatory, infectious and mixed inflammatory-infectious lung diseases, in particular SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), or Covid-19.
- the present invention provides gold-containing agents for therapy and their use for the treatment of infectious and mixed inflammatory-infectious lung diseases in which the active ingredient is preferably inhaled directly to the site of action in the lungs and can develop its effect there. This application also reduces side effects to the lowest possible level.
- Microbial infections are usually accompanied by inflammatory processes. This finding is not a coincidental coincidence, but rather is due to synchronous germ-host interactions. It has therefore been shown that active ingredients with dual anti-infective and anti-inflammatory effects are particularly suitable for the treatment of microbial infections.
- the dual effect of the gold compounds can offer a particular advantage because the anti-inflammatory effect is achieved by inhibiting the nuclear factor NFkappa B (Bodas M. and Vij N, 2010), which is involved in the development of interstitial pneumonia, among other things.
- the anti-inflammatory effect of the agents according to the invention is comparable to that of inhaled steroids (see e.g. Example 3).
- Gold-containing agents according to the invention are particularly preferred for the treatment of diseases caused by Coronaviridae belonging to the group of RNA viruses, such as SARS (Severe Acute Respiratory Syndrome) MERS-CoV (Middle East Respiratory Syndrome Corona Virus) and SARS-CoV-2.
- the gold-containing agents according to the invention namely bind with high affinity to mercapto groups of cysteine-rich domains of binding proteins of these viruses, in particular of corona viruses, which is functionally essential for their binding to the host cells and the fusion (Chang et al, 2000 , Broer et al., 2006).
- these viral diseases are often accompanied by bacterial superinfections with biofilm formation, against which the agents according to the invention also act.
- Auranofin and other gold complexes inhibit the interaction of the spike protein of SARS-CoV-2 with the ACE2 receptor (ACE2: Angiotensin Converting Enzyme 2). Further inhibit Gold complexes the activity of the viral protease PLpro (PLpro: Pa-pain-Like Protease) of SARS-CoV-1 and SARS-CoV-2. Auranofin showed IC 50 values of 22.2 mM against the Spike / ACE2 interaction and 0.75 mM against PLpro of SARS-CoV-2. (Gil-Moles et al., 2020)
- the preferred form of application of the agents is inhalation as a liquid aerosol or by powder inhalation.
- the latter is distinguished from the easier-to-use liquid inhalation, in which considerable amounts of the active ingredient get stuck in the throat, through a more precise option for dosing.
- Elemental gold can be used in the form of nanoparticles, but the drugs aurothioglucose, aurothiomalate and auranofin, which have been tried and tested in anti-rheumatic practice, and the auroacetylcysteine salt, in which the gold is in ionic form, are preferred.
- Aurothioglucose has the advantage that the gold ion is particularly strongly bound to the molecule and is therefore released in a controlled manner.
- aqueous solutions of the agents according to the invention can be added to the breathing air by means of spray nozzles.
- micronization of the active ingredient is a preferred form of application, because deeper lung areas are reached.
- Use in a mixture with a carrier is also preferred.
- Mixing the micronized active ingredient with a carrier with a larger grain size is particularly preferred because it ensures that the carrier is initially deposited in the higher areas of the pharynx and the active ingredient increasingly penetrates deeper lung areas. Lactose, mannose and other carbohydrates are particularly suitable as carrier substances.
- the active ingredients are present in separate compartments of a powder inhaler. Bringing the active ingredients into separate compartments facilitates production, among other things.
- gold or aurothioglucose and N-acetylcysteine are therefore present in separate compartments of the powder inhaler.
- gold or aurothioglucose and the antiviral are in separate compartments of the powder inhaler.
- the triple- All three active ingredients can be combined in separate compartments of the powder inhaler.
- the medicament for use according to the invention contains a gold-containing antirheumatic medicament.
- Particularly preferred anti-rheumatic drugs are aurothioglucose, aurothiomalat, auranofin, aurothiosulfate, aurotioprol, and / or aurothiopolypeptide.
- aurothioglucose has proven to be particularly advantageous in connection with the invention.
- the medicament preferably contains auxiliary substances. Particularly preferred are auxiliaries such as are usually used in formulations for inhalation, in particular powder and liquid formulations for inhalation.
- the medicament contains a carrier, preferably a carbohydrate, particularly preferably lactose and / or mannose.
- the medicament contains a further active ingredient for use, preferably wherein the further active ingredient has an antiviral and / or antibacterial effect.
- Antivirals are particularly preferred, in particular favipiravir, molnupiravir, remdesivir or ribavirin.
- the lung disease is preferably a lung infection, preferably a viral or mixed viral-bacterial lung infection, even more preferably a disease caused by coronaviruses belonging to the group of RNA viruses, in particular SARS-CoV-1, SARS- CoV-2 or MERS-CoV. It is therefore preferably a corona virus infection, in particular a SARS-CoV-1 infection, a SARS-CoV-2 infection or a MERS-CoV infection.
- the lung disease is particularly preferably SARS (triggered by a SARS-CoV-1 infection), Covid-19 (triggered by a SARS-CoV-2 infection), or MERS (triggered by a MERS-CoV infection) .
- the medicament is preferably used by inhalation.
- Liquid inhalation or powder inhalation is particularly preferred.
- the dual-acting drug according to the invention contains gold (preferably in the form of aurothioglucose, aurothiomalat, auranofin, aurothiosulfate, aurotioprol, and / or aurothiopolypeptide and no other active substances.
- gold preferably in the form of aurothioglucose, aurothiomalat, auranofin, aurothiosulfate, aurotioprol, and / or aurothiopolypeptide and no other active substances.
- the medicament according to the invention contains gold (preferably in the form of aurothioglucose, aurothiomalate, auranofin, aurothiosulfate, aurotioprol, and / or aurothiopolypeptide, in particular aurothioglucose) and N-acetylcysteine in a molar ratio of between 1: 40 and 10: 1, preferably between 1:20 and 5: 1, more preferably between 1:10 and 2.5: 1, even more preferably between 1: 5 and 1: 1, even more preferably between 1: 2, 5 and 1: 1.5, most preferably 1: 2 (gold: N-acetylcysteine).
- gold preferably in the form of aurothioglucose, aurothiomalate, auranofin, aurothiosulfate, aurotioprol, and / or aurothiopolypeptide, in particular aurothioglucose
- the medicament is present as a formulation for inhalation. It is particularly preferred if the formulation is a powder formulation.
- the medicament is preferably in the form of a dry powder for aerosol preparation.
- a powder formulation enables particularly simple administration, e.g. through a powder inhaler.
- powder inhalers can be used, as they are already used for the treatment of asthma or COPD.
- the medicament is preferably in micronized form.
- the medicament is in the form of a powder or solution for aerosol preparation.
- This formulation is particularly suitable for administration by metered dose inhalers or nebulizers.
- metered dose inhalers or nebulizers can also be used for patients who are artificially ventilated, for example in the case of severe courses of coronavirus infections, in particular SARS, Covid-19 or MERS.
- the inhaler according to the invention is a powder inhaler, the medicament according to the invention being in the form of a powder formulation.
- the inhaler is a metered dose inhaler (e.g. a pressurized metered dose inhaler or a normal pressure metered dose inhaler) or nebulizer, the medicament according to the invention being present as a solution or as an aerosol.
- the invention further discloses a method for the prevention or treatment of a lung disease, preferably an infectious or mixed inflammatory-infectious lung disease, comprising the steps: - providing a medicament or a combination medicament as described herein; and
- the method is for treating the pulmonary disease in which the individual suffers from the pulmonary disease.
- All preferred embodiments for the medicament for use according to the invention are also considered to be preferred for the method of treatment disclosed here.
- all preferred embodiments of the lung disease are also considered to be preferred for this method.
- the medicament is preferably administered through an inhaler according to the invention.
- prevention means to prevent the occurrence of a disease in an individual completely or almost completely or at least to a (preferably significant) extent. However, this term should not be interpreted as an absolute success in the sense that the individual can never develop such a disease, but rather as a reduction in the risk of the disease.
- the terms “agent”, “medicament” or “pharmaceutical composition” are understood to mean a composition containing at least one active ingredient and preferably containing one or more pharmaceutically acceptable auxiliaries Animal, preferably a mammal, most preferably a human.
- a dose of the drug is administered to an indi viduum, it being preferred that a dose of the drug is administered at least once a week, preferably at least every two days, more preferably at least once a day, even more preferably at least twice a day , in particular at least three times a day.
- the therapy is preferably carried out over a period of time and with an effective amount of drug. It is particularly preferred if the medicament is administered over a period of 1 to 30 days, preferably from 2 to 21 days, even more preferably from 3 to 14 days, most preferably from 5 to 10 days.
- treating individual preferably an animal, preferably a mammal, in particular a human.
- the individual has one of the lung diseases described herein.
- the concentration of gold in a dose of the drug is between 0.001 mpio ⁇ and 450 mpio ⁇ , preferably between 0.01 mpio ⁇ and 250 mpio ⁇ , even more preferably between 0.1 mpio ⁇ and 50 mpio ⁇ , most preferably between 0, 5 mpio ⁇ and 30 mpio ⁇ .
- a dose contains between 0.1 pg and 1000 pg gold per kg of body weight of the patient, preferably between 0.2 pg / kg and 200 pg / kg, more preferably between 0.5 pg / kg and 40 pg / kg, most preferably between 1 pg / kg and 10 pg / kg body weight.
- Embodiment Al Medicines for inhalation containing gold, preferably aurothioglucose, aurothiomalate, auranofin, aurothiosulphate, aurotioprol, aurothiopolypeptide, and / or the gold salt of a sulfur-containing drug (preferably N-acetylcysteine, pyritinol, tiopronin and / or auricillamine), in particular auricillamine .
- a sulfur-containing drug preferably N-acetylcysteine, pyritinol, tiopronin and / or auricillamine
- Embodiment A2 Medicament according to embodiment A1, characterized in that the medicament contains a gold-containing antirheumatic medicament, preferably aurothioglucose, aurothioglucose, aurothio malate, auranofin, aurothiosulfate, aurotioprol, and / or aurothio polypeptide, in particular aurothioglucose.
- a gold-containing antirheumatic medicament preferably aurothioglucose, aurothioglucose, aurothio malate, auranofin, aurothiosulfate, aurotioprol, and / or aurothio polypeptide, in particular aurothioglucose.
- Embodiment A3 Medicines for inhalation containing aurothioglucose.
- Embodiment A4 Medicament according to one of the embodiments A1 to A3, furthermore containing N-acetylcysteine.
- Embodiment A5. Medicament according to one of the embodiments A1 to A4, characterized in that the medicament contains a further active substance, preferably wherein the further active substance has an antiviral and / or antibacterial effect.
- Embodiment A6. Medicament according to one of the embodiments A1 to A5, furthermore containing a virostat, preferably selected from the group consisting of remdesivir, molnupiravir, favipiravir, ribavirin, lopinavir, umifenovir, nelfinavir and / or ritonavir, preferably favipiravir, molnupiravir and / or ribavirin, in particular Favipiravir.
- Embodiment A7. Medicament according to one of the embodiments A1 to A6, furthermore containing an active ingredient selected from hydroxychloroquine, chloroquine and / or ivermectin.
- Embodiment A8 Containing medicaments for inhalation
- Gold preferably aurothioglucose, aurothiomalate, auranofin, aurothiosulfate, aurotioprol, aurothiopolypeptide, and / or the gold salt of a sulfur-containing drug (preferably N-acetylcysteine, pyritinol, tiopronine and / or penicillamine), in particular aurothioglucose;
- a sulfur-containing drug preferably N-acetylcysteine, pyritinol, tiopronine and / or penicillamine
- a virostat preferably selected from the group consisting of remdesivir, molnupiravir, favipiravir, ribavirin, lopinavir, umifenovir, nelfinavir and / or ritonavir, preferably favipiravir, molnupiravir and / or ribavirin, in particular Favi piravir; and
- Embodiment A9 Medicament according to one of the embodiments A1 to A8, characterized in that the medicament gold and N-acetylcysteine in a molar ratio of between 1:40 and 10: 1, preferably between 1:20 and 5: 1, more preferably between 1:10 and 2.5: 1, even more preferably between 1: 5 and 1: 1, even more preferably between 1: 2.5 and 1: 1.5, most preferably 1: 2 (gold: N-acetylcysteine).
- Embodiment A10 Medicament according to one of the embodiments A1 to A9, characterized in that the medicament aurothioglucose and N-acetylcysteine in a molar ratio of between 1:40 and 10: 1, preferably between 1:20 and 5: 1, more preferably between 1: 10 and 2.5: 1, even more preferably between 1: 5 and 1: 1, even more preferably between 1: 2.5 and 1: 1.5, most preferably 1: 2 (aurothioglucose: N-acetylcysteine) .
- the medicament contains a carrier, preferably a carbohydrate, particularly preferably lactose and / or mannose.
- Embodiment A12. Medicament according to one of the embodiments A1 to All, characterized in that the medicament is in the form of a powder formulation, preferably micronized.
- Embodiment A13 Medicament according to one of theticiansfor men Al to All, characterized in that the medicament is present as a solution or as an aerosol.
- Inhaler preferably powder inhaler, metered dose inhaler or nebuliser, containing a medicament according to one of the embodiments A1 to A13.
- Embodiment Al5. Inhaler, preferably powder inhaler, containing a medicament according to embodiment A12.
- Embodiment A16 Inhaler, preferably metered dose inhaler or nebulizer, containing a medicament according to embodiment A13.
- Embodiment A17 Powder inhaler containing a medicament according to one of the embodiments A4 to A12, characterized in that gold or aurothioglucose and N-acetylcysteine are present in separate compartments of the powder inhaler.
- Embodiment A18 Powder inhaler containing a medicament according to one of the embodiments A5 to A12, characterized in that gold or aurothioglucose and the further active ingredient are present in separate compartments of the powder inhaler.
- Embodiment A19 Powder inhaler containing a medicament according to one of the embodiments A6 to A12, characterized in that gold or aurothioglucose and the antiviral are present in separate compartments of the powder inhaler.
- Embodiment A20 Medicaments according to one of theticiansfor men A1 to A13 for use in the prevention or therapy of lung diseases, preferably in the prevention or therapy of inflammatory, infectious and mixed inflammatory-infectious lung diseases.
- Embodiment A21 Medicament for use according to embodiment A20, characterized in that the lung disease is an infectious or a mixed inflammatory-infectious lung disease.
- Embodiment A22 Medicament for use according to one of the embodiments A20 or A21, characterized in that the lung disease is a lung infection, preferably a viral or mixed viral-bacterial lung infection, even more preferably a disease caused by Coronaviridae belonging to the group of RNA viruses, in particular SARS -CoV-1, SARS-CoV-2 or MERS-CoV.
- the lung disease is a lung infection, preferably a viral or mixed viral-bacterial lung infection, even more preferably a disease caused by Coronaviridae belonging to the group of RNA viruses, in particular SARS -CoV-1, SARS-CoV-2 or MERS-CoV.
- Embodiment A23 Medicament for use according to one of the embodiments A20 to A22, characterized in that the lung disease is SARS, MERS, or Covid-19.
- Embodiment A24 Medicines for use according to embodiment A20, characterized in that the lung disease is a inflammatory lung disease, preferably a chronic inflammatory lung disease, especially COPD, cystic fibrosis or interstitial pneumonia.
- the lung disease is a inflammatory lung disease, preferably a chronic inflammatory lung disease, especially COPD, cystic fibrosis or interstitial pneumonia.
- Embodiment A25 Medicament for use according to one of the embodiments A20 to A24, characterized in that the medicament in a dose containing between 0.001 mpio ⁇ and 450 mpio ⁇ , preferably between 0.01 mpio ⁇ and 250 mpio ⁇ , even more preferably between 0.1 mpio ⁇ and 50 mpio ⁇ , most preferably between 0.5 mpio ⁇ and 30 mpio ⁇ gold is administered.
- Embodiment A26 Medicament for use according to one of the embodiments A20 to A25, characterized in that the medicament in a dose containing between 0.1 pg and 1000 pg gold per kg body weight of the patient, preferably between 0.2 pg / kg and 200 pg / kg, more preferably between 0.5 pg / kg and 40 pg / kg, most preferably between 1 pg / kg and 10 pg / kg body weight gold is administered.
- Embodiment A27 Medicament for use according to one of the embodiments A20 to A26, characterized in that the use takes place by inhalation, preferably liquid inhalation or powder inhalation.
- Embodiment A28 Medicament for use according to one of the embodiments A20 to A27, characterized in that the application takes place through an inhaler according to one of the embodiments A14 to A19.
- Embodiment A27 A method for the prevention or treatment of a lung disease, preferably a lung disease as defined in one of the embodiments A20 to A26, comprising the steps:
- Embodiment A28 Method according to embodiment A27, wherein the method is defined as in one of embodiments A20 to A26.
- Embodiment A29 Method according to embodiment A27 or A28, characterized in that the medicament is administered by an inhaler, preferably by an inhaler according to one of the embodiments A14 to A19.
- Embodiment Bl Means for the therapy of inflammatory, infectious and mixed inflammatory-infectious lung diseases, characterized in that they contain gold.
- Embodiment B2 Agents according to embodiment B1 characterized in that they are used for inhalative therapy of lung infections.
- Embodiment B3 Agents according to embodiment B1 characterized in that they are used for inhalative therapy of viral and mixed viral-bacterial lung infections.
- Embodiment B6 Agent according to embodiments B1-B4, characterized in that the anti-rheumatic drug is aurothio malate.
- Embodiment B7 Agent according to embodiments B1-B4, characterized in that the anti-rheumatic drug is auranofin
- Embodiment B8 Agent according to embodiments B1-B4, characterized in that the active ingredient is the gold salt of an acidic medicinal substance, preferably N-acetylcysteine.
- Embodiment B9 Agent according to embodiment B1-B8, characterized in that it is used by liquid inhalation.
- Embodiment BIO Agent according to embodiment B1-B8, characterized in that it is used by powder inhalation.
- Embodiment B12 Agent according to embodiment BIO and BIl, characterized in that the carrier is a carbohydrate, preferably lactose or mannose.
- Embodiment B13 Agent according to the embodiment BIO characterized in that the medicinal substance is used in micronized form.
- Embodiment B14 Medicament according to embodiments B1-B13, characterized in that at least one further Active ingredient is included.
- Embodiment B15 Agent according to embodiment B14 characterized in that the additional active ingredient has an antiviral effect.
- Embodiment B16 Agent according to embodiments B14 and B15, characterized in that the additional active ingredient has an anti-bacterial effect.
- Embodiment B17 The use of agents according to execution forms B1-B16 for the treatment of infectious and mixed inflammatory infectious diseases of the respiratory tract.
- Embodiment B18 The use of agents according to embodiment B17 for the treatment of diseases caused by Coronaviridae belonging to the group of RNA viruses, such as SARS (Severe Acute Respiratory Syndrome), MERS-CoV (Middle East Respiratory Syndrome Corona Virus), SARS-CoV- 2 and Covid-19.
- SARS severe Acute Respiratory Syndrome
- MERS-CoV Middle East Respiratory Syndrome Corona Virus
- SARS-CoV- 2 Covid-19.
- Embodiment B19 The use of agents according to embodiment B1-B16 for the treatment of inflammatory lung diseases, preferably chronic inflammations, such as COPD, cystic fibrosis and interstitial pneumonia.
- inflammatory lung diseases preferably chronic inflammations, such as COPD, cystic fibrosis and interstitial pneumonia.
- Embodiment B20 The use of auroacetylcysteine in medicaments according to embodiments B17-B19.
- Fig. 1 Anti-inflammatory efficacy of auroacetylcysteine in a mouse model for acute allergic asthma: experimental set-up.
- Fig. 3 Anti-inflammatory efficacy of auroacetylcysteine in a mouse model for acute allergic asthma: histological examination of the lung tissue.
- Fig. 4th Anti-inflammatory efficacy of auroacetylcysteine in a mouse model for acute allergic asthma Examination of the lung tissue with HE and LUNA stains.
- the specified ratios relate to the molar ratios.
- Fig. 8 Activating influence of added N-acetylcysteine on the inhibition of the spike / ACE2 interaction by 20 mM aurothioglucose. N-acetylcysteine alone does not inhibit the spike / ACE2 interaction (97% of the control at 100 mM).
- the specified ratios relate to the molar ratios.
- AF auranofin
- AM aurothiomalate
- AG aurothioglucose
- N N-acetylcysteine
- Fig. 10 Removal of zinc from the PLpro by disulfiram, aurothioglucose (AG) and the mixture of aurothioglucose with N-acetylcysteine in a molar ratio of 1: 2 (AG-N). (Values given in comparison to untreated enzyme (PLpro)).
- Example 1 Preparation of single doses for inhalation.
- l.a. Liquid ampoule A solution of 1.5 mg Auranofin in 2.5 ml water containing sodium chloride is placed in a single-dose container and placed in a nebuliser for use.
- Dry ampoule One ampoule is filled with 1.5 mg aurothioglucose. Before use, 2.5 ml of water is injected and the solution is placed in an inhaler. The finished product must be used within 3 hours.
- Powder spray 30 mg of micronized aurothioglucose will be suspended in 300 microliters of ethanol. 30 mg of sorbitan trioleate are added and, while cooling, 15 g of propellant are added in a spray can, which sprays the product in 300 strokes.
- Dry inhaler 0.2 mg micronized aurothioglucose is mixed with 12 mg lactose and prepared for powder inhalation with strict exclusion of moisture. This depends on the type of inhaler and, if necessary, can be pressed into a disc.
- Example 3 Proof of the anti-inflammatory effect of inhaled auroacetylcysteine in a preclinical pilot study in a mouse model for acute allergic asthma by means of application via the nose.
- AAC auroacetylcysteine
- the reduction in the total number of cells was comparable to that of dexamethasone.
- the inflammation of the lung tissue was determined by means of histological examination (FIG. 3), HE and LUNA staining (FIG. 4), the mucus production by means of PAS staining.
- FIG. 3 histological examination
- HE and LUNA staining FIG. 4
- AAC mainly reduces eosinophils and neutrophils, as well as lymphocytes. Macrophages are increased compared to dexamethasone.
- the serum-specific Ag - IgGl (ELISA) was also measured.
- Auroacetylcysteine at a concentration of 10 mg / kg reduces the inflammation parameters both peribronchiolar and in the parenchyma.
- the anti-inflammatory effect in the tissue is comparable to that of dexamethasone.
- Treating mice with acute exacerbations of allergic asthma with 10 mg / kg auroacetylcysteine for 5 days reduces the total number of inflammatory cells in bronchial secretions, the extent of inflammation in the airways, the number of eosinophils and neutrophils in the airways, the infiltrates of inflammatory cells in the lung parenchyma.
- Example 5 Inhibition of the SARS-CoV-2 protease PLpro by gold compounds.
- the inhibition of the SARS-CoV-2 protease Papain-Like Protease was determined as follows: The test substances were dissolved as stock solutions in water and 100 times with HEPES buffer (50 mM HEPES, pH 7.5, 0.1 mg / mL bovine serum albumin, 0.1% Triton-X-100) diluted so that micromolar concentrations were achieved. Volumes of 50 pL of a 200 nM solution of SARS-CoV-2 PLpro in HEPES buffer or pure HEPES buffer (negative control) were pipetted into the wells of a black 96-well microtiter plate.
- HEPES buffer 50 mM HEPES, pH 7.5, 0.1 mg / mL bovine serum albumin, 0.1% Triton-X-100
- the percentage calculation of the enzyme activity was made in relation to the untreated control (positive control).
- the results of the negative controls were used to determine the absence of false positive results, such as by Confirm the reaction of the test substance with the substrate.
- the IC 50 values were calculated as the concentration at which the test substance inhibits the enzyme activity by 50% compared to the positive control.
- Example 6 Inhibition of the interaction of the SARS-CoV-2 spike protein with the ACE2 receptor.
- the influence of the test substances on the spike / ACE2 interaction can be determined by ELISA.
- a 96-well plate was coated with the receptor binding domain of the spike protein and stored at 4 ° C. overnight.
- the wells of the microtiter plate were emptied, a blocking solution was added for 2 hours, washed and emptied.
- the test substances and controls were added as a mixture with the ACE2 receptor and incubated at 37 ° C. for one hour. The wells were washed.
- Horseradish peroxidase conjugated with streptavidin was added and incubated for one hour at room temperature. After a further wash, a solution containing 3,3 ', 5,5'-tetramethylbenzidine was added. After 5 minutes at room temperature, the absorption at 450 nm was determined (Perkin Elmer Victor X4 microplate reader). The activity remaining after the addition of inhibitor was calculated as a percentage in relation to the untreated control.
- CaLu-3 cells were grown in 96-well microtiter plates.
- the cell culture medium was replaced by fresh medium which contained the gold compounds in concentrations of 25, 50 or 100 mM and incubated for 24 hours at 37 ° C / 5% CO2.
- the remaining amount of cells was then determined photometrically by means of crystal violet staining (Victor X4 microplate reader). The amount of cells in the treated samples was calculated as a percentage in relation to an untreated control.
- the protease PLpro contains other cysteines in a zinc binding domain, which stabilize the structure and function of the enzyme. The removal of the bound zinc represents an interesting mechanism of action for inhibitors of PLpro.
- the presence of the Zn 2+ cation in solution was determined as follows.
- the inhibitor compounds were prepared as stock solutions in DMSO as stock solutions in water or DMSO and diluted a hundredfold with HEPES buffer (50 mm HEPES, pH 7.5) to 100 mM concentrations. Volumes of 50 pL of SARSCoV-2 PLpro (Elabscience) in HEPES buffer or empty HEPES buffer (control for false positive results) were added to the wells of a black 96-well microtiter plate (Nunclon, Nunc). Volumes of 50 pL of the inhibitor solutions or 1% DMSO in HEPES buffer (control) were added.
- the relative fluorescence was calculated by dividing the absolute fluorescence emission of the well which contained the inhibitor by the absolute fluorescence of the corresponding well which contained the enzyme but no inhibitor (control). Wells that contained the inhibitor but no enzyme were used to check for false positive results. None of the compounds tested showed false positive results.
- aurothioglucose resulted in a removal of zinc from the PLpro comparable to that of the reference compound disulfiram.
- Example 9 Inhibition of the SARS-CoV-2 protease 3CLpro by gold compounds.
- the inhibition of the SARS-CoV-2 protease 3CLpro was determined as follows: The test substances were dissolved as stock solutions in water and 100 times with HEPES buffer (50 mM HEPES, pH 7.5,
- 0.1 mg / mL bovine serum albumin, 0.1% Triton-X-100 diluted so that micromolar concentrations were achieved.
- Volumes of 50 pL of a 300 nM solution of SARS-CoV-23CL protease (Mpro) MBP-tag in HEPES buffer or pure HEPES buffer (negative control) were pipetted into the wells of a black 96-well microtiter plate.
- 50 pL of the solutions of the test substances or pure HEPES buffer (positive control) were added and the resulting solutions were mixed and incubated at 37 ° C. for one hour.
- the gold compounds are good inhibitors of SARS-CoV-2 3CLpro.
- the following IC50 values were determined: Auranofin: 11.69 pM ( ⁇ 0.40 pM); Aurothioglucose: 8.25 pM ( ⁇ 0.04 pM); Aurothiomalate: 22.89 mM ( ⁇ 0.72 mM).
- Bovine coronavirus a virus related to SARS-CoV-2, which is also classified in the genus Betacoronavirus is used, since experiments with these sem can be carried out in the lower biological protection level BSL2.
- Madin Darby Bovine Kidney (MDBK) cells were used as susceptible cell cultures.
- aurothioglucose-bovine coronavirus suspension was inoculated onto the MDBK cells susceptible to this virus and used for Incubated for 12 - 48 hours at 37 ° C and 5% CO2 atmosphere.
- aurothioglucose concentration 256 mM, a 10-fold reduction in the amount of virus was found.
- micronized aurothioglucose 3 mg are mixed with 9 mg of lactose and made available in a multi-dose powder inhaler.
- Four Covid-19 patients with onset of symptoms within 48 hours before the start of treatment are administered 2 puffs of 200 pg of the powder formulation twice a day over a period of 10 days.
- liquid ampoules with 0.1 mg each of aurothioglucose and 0.4 mg of N-acetylcysteine dissolved in 2.5 mL of water are produced.
- Four Covid-19 patients under artificial respiration are given a liquid ampoule per day via a nebuliser over a period of 10 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA60074/2020A AT523662B1 (de) | 2020-03-16 | 2020-03-16 | Gold-haltige Mittel zur Behandlung von Lungeninfektionen |
PCT/EP2021/056554 WO2021185773A1 (fr) | 2020-03-16 | 2021-03-15 | Agents contenant de l'or pour le traitement d'infections pulmonaires |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4121066A1 true EP4121066A1 (fr) | 2023-01-25 |
Family
ID=74884976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21712492.4A Pending EP4121066A1 (fr) | 2020-03-16 | 2021-03-15 | Agents contenant de l'or pour le traitement d'infections pulmonaires |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230128434A1 (fr) |
EP (1) | EP4121066A1 (fr) |
JP (1) | JP2023528127A (fr) |
KR (1) | KR20220154220A (fr) |
CN (1) | CN115484965B (fr) |
AT (1) | AT523662B1 (fr) |
AU (1) | AU2021238580A1 (fr) |
CA (1) | CA3171788A1 (fr) |
MX (1) | MX2022011434A (fr) |
WO (1) | WO2021185773A1 (fr) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60141703D1 (de) * | 2000-10-16 | 2010-05-12 | Univ Duke | Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose |
WO2012142615A2 (fr) * | 2011-04-14 | 2012-10-18 | Board Of Regents, The University Of Texas System | Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs |
KR101705412B1 (ko) * | 2014-06-17 | 2017-02-09 | 가톨릭대학교 산학협력단 | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
WO2016201524A1 (fr) * | 2015-06-19 | 2016-12-22 | Rr Medsciences Pty Ltd | Complexes d'ions métalliques |
WO2017058012A1 (fr) * | 2015-09-29 | 2017-04-06 | Rijksuniversiteit Groningen | Composés d'or(iii) utilisés comme inhibiteurs de la phosphatase acide résistante au tartrate et leurs utilisations thérapeutiques |
GB201521239D0 (en) * | 2015-12-02 | 2016-01-13 | Auspherix Ltd | Anti-bacterial compounds |
US20210007982A1 (en) * | 2019-07-12 | 2021-01-14 | Attostat, Inc. | Use of nanoparticles for treating respiratory infections associated with cystic fibrosis |
-
2020
- 2020-03-16 AT ATA60074/2020A patent/AT523662B1/de active
-
2021
- 2021-03-15 WO PCT/EP2021/056554 patent/WO2021185773A1/fr unknown
- 2021-03-15 KR KR1020227035926A patent/KR20220154220A/ko unknown
- 2021-03-15 EP EP21712492.4A patent/EP4121066A1/fr active Pending
- 2021-03-15 MX MX2022011434A patent/MX2022011434A/es unknown
- 2021-03-15 US US17/906,241 patent/US20230128434A1/en active Pending
- 2021-03-15 JP JP2022556110A patent/JP2023528127A/ja active Pending
- 2021-03-15 CN CN202180022150.0A patent/CN115484965B/zh active Active
- 2021-03-15 CA CA3171788A patent/CA3171788A1/fr active Pending
- 2021-03-15 AU AU2021238580A patent/AU2021238580A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AT523662A1 (de) | 2021-10-15 |
MX2022011434A (es) | 2022-10-18 |
JP2023528127A (ja) | 2023-07-04 |
AU2021238580A1 (en) | 2022-10-06 |
CN115484965B (zh) | 2024-06-18 |
WO2021185773A1 (fr) | 2021-09-23 |
CN115484965A (zh) | 2022-12-16 |
KR20220154220A (ko) | 2022-11-21 |
AT523662B1 (de) | 2023-07-15 |
US20230128434A1 (en) | 2023-04-27 |
CA3171788A1 (fr) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69933208T2 (de) | Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt | |
EP1307189B1 (fr) | Utilisation d'hydroxyethylrutosides pour traiter les symptomes du rhume, la rhinite allergique et les infections liees aux voies respiratoires | |
DE60318237T2 (de) | Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol | |
US20220257642A1 (en) | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract | |
AU2001279587A1 (en) | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract | |
EP2640410B1 (fr) | Composition comprenant un peptide et un inhibiteur de la neuraminidase virale | |
EP2385835B1 (fr) | Utilisation d'oxyde de deutérium pour le traitement d'affections virales de l'oeil | |
DE102008004386A1 (de) | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen | |
Voshaar et al. | A randomized study of tiotropium Respimat® Soft MistTM Inhaler vs. ipratropium pMDI in COPD | |
US20220370493A1 (en) | Methods and compositions for generating nitric oxide and uses thereof | |
NO331524B1 (no) | Anvendelse av ciprofloksacin betain for fremstilling av medikamenter og aerosolinnretning for administrering av fast aktivbestanddel ved inhalering. | |
EP2320878B1 (fr) | Monoterpène pour le traitement de maladies des voies respiratoires, en particulier de maladies bronchopulmonaires | |
EP2110132A1 (fr) | Utilisation d'oxyde de deutérium en tant qu'inhibiteur d'élastase | |
EP1599194B1 (fr) | Utilisation de l'acide acetylsalicylique destinees a la prophylaxie et/ou la therapie de maladies virales | |
RU2013103051A (ru) | Способ терапии бронхо-констриктивных состояний | |
WO2021185773A1 (fr) | Agents contenant de l'or pour le traitement d'infections pulmonaires | |
DE2903957A1 (de) | Mittel zur behandlung der nasalen hypersekretion | |
KR20050085104A (ko) | 로플루미래스트와 포르모테롤을 포함하는 신규한상승작용성 조합물 | |
US20230172973A1 (en) | Methods and compositions for treating and combatting tuberculosis | |
EP2385834B1 (fr) | Utilisation d'oxyde de deutérium pour le traitement d'affections virales des voies respiratoires | |
KR20210031466A (ko) | 상승 작용량의 붕산을 이용한 뎁시펩타이드 항생제의 항균 작용 증진 | |
US20020151562A1 (en) | Compositions and methods for treating allergic fungal sinusitis | |
WO2012004330A1 (fr) | Inhibiteur nos l-nil dans son application pour des maladies pulmonaires chroniques | |
US20220273594A1 (en) | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections | |
RU2619855C1 (ru) | Интраназальная фармацевтическая композиция на основе инсулина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220913 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AUROVIR PHARMA GMBH |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |